Revolution Medicines CFO Sells $6.7 Million in Shares

Revolution Medicines chief financial officer Jack Anders sold 35,750 shares on Wednesday, November 11, generating $6,724,575 at an average price of $188.10 per share. The disposal reduced his direct ownership by 23.07%, leaving him with 119,216 shares worth $22,424,529.60, according to a legal filing with the Securities and Exchange Commission. A trim, then. Not an exit.

Was this a one-off?

It was not. On Wednesday, September 16, Mr. Anders sold 4,053 shares at an average price of $199.24, for a total of $807,519.72. Two disposals in three months, both near the stock's upper range, will invite the usual scrutiny that follows insider selling at clinical-stage biotechnology firms (companies whose drugs remain in development rather than on the market).

The context is a share price that has climbed considerably. Revolution Medicines trades on the NASDAQ under the ticker RVMD, and on Friday the stock fell $4.06 to $172.29, a decline of 2.3%. Volume reached 2,654,066 shares, slightly below the average of 2,814,289.

What do the fundamentals say?

The market capitalization stands at $37.26 billion. The price-to-earnings ratio (a valuation measure dividing share price by profit per share) is negative at -18.91, which is expected for a company yet to post profits. The beta, a measure of volatility relative to the broader market, reads 1.44.

Liquidity is ample. The current ratio (short-term assets divided by short-term liabilities) is 8.36, the quick ratio is 8.34, and the debt-to-equity ratio sits at 0.44. The 50-day moving average price is $195.24 and the 200-day figure is $159.06, so the stock remains above its longer-term trend despite recent softness. The 12-month range runs from $63.50 to $224.31.

The company last reported quarterly results on Wednesday, November 4. It posted a loss of $1.90 per share, beating the consensus estimate of a $2.35 loss by $0.45. Revenue came in at $197.56 million against analyst expectations of $25.58 million. In the same quarter a year earlier, the loss was $1.61 per share. Analysts on average expect a full-year loss of $7.41 per share for the current fiscal year.

Who else is buying and selling?

Institutional investors hold 94.34% of the company's stock, and several large names have added positions recently:

• Alphabet Inc. bought a new position in the second quarter worth approximately $551,843,000.
• Assenagon Asset Management S.A. increased its holding by 987.9% in the third quarter, adding 1,980,699 shares to own 2,181,185 shares valued at $447,710,000.
• ABS Investment Management LLC acquired a new second-quarter stake of roughly $337,104,000.
• Winslow Capital Management LLC opened a new third-quarter position of approximately $260,191,000.
• Bank of America Corp DE bought a new second-quarter stake worth about $184,267,000.

One CFO trimming; several institutions building. The ledger, at least, is unambiguous about which side holds the heavier money.

What do analysts expect?

Sell-side coverage remains broadly constructive. TD Cowen raised its target price from $250.00 to $270.00 with a "buy" rating on Thursday, November 5. Oppenheimer lifted its target from $230.00 to $260.00 with an "outperform" rating on Thursday, August 27, and Evercore reiterated "outperform" with a $320.00 target the same day. UBS Group moved its objective from $220.00 to $265.00 with a "buy" rating on Friday, August 28. Brookline Capital Markets initiated coverage on Monday, September 28, setting a "buy" rating and a $318.00 target.

The ratings distribution breaks down as follows: one Strong Buy, twenty-one Buy, one Hold and one Sell. According to MarketBeat, the consensus rating is "Moderate Buy" with an average target price of $262.75 — comfortably above the current quote of $172.29, should one place faith in such arithmetic.

What does the company actually do?

Revolution Medicines, founded in 2014 and headquartered in Redwood City, California, develops targeted therapies for RAS-driven cancers (tumors fueled by mutations in a family of proteins that regulate cell growth). Its pipeline includes daraxonrasib, known as RMC-6236, which targets multiple RAS variants, alongside candidates directed at specific KRAS mutations.

For the finance desk, the summary is straightforward. A CFO realized roughly $6.7 million at prices below the stock's recent high; institutions continue to accumulate; and the analyst consensus, if not the insider, remains on the optimistic side of the ledger.